A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Inclusion Criteria:

* First generation Japanese; subject was born in Japan and has not lived outside of Japan for \> 10 years, and subject can trace maternal and paternal Japanese ancestry.
* Histologically confirmed aggressive/indolent DLBCL, FL, MZL, or MCL.
* Previously received at least 1 prior line of systemic therapy with documented progression, and there is no further effective standard anticancer therapy available.
* Willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue.
* Life expectancy \> 3 months.
* Eastern Cooperative Oncology Group performance status of 0 to 2.
* Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

* Evidence of transformed non-Hodgkin's lymphoma histologies.
* Histologically confirmed, rare non-Hodgkin's B-cell subtypes.
* History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.
* Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-phosphatidylinositol 3 kinase (PI3K) inhibitor.
* Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug.
* Active graft-versus-host disease.
* History of stroke or intracranial hemorrhage within 6 months of study drug administration.
* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment or exposure to a live vaccine within 30 days of the date of the first dose of study drug.
* Known human immunodeficiency virus infection.
* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.